Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLX-103
- Development stage
- Preclinical
- Lead developer
- Cellix Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CLX-103** is an orally administered, investigational small-molecule prodrug molecular conjugate developed for mild to moderate ulcerative colitis. Generated using Cellix Bio's Synergix platform, it covalently links mesalamine with eicosapentaenoic acid and caprylic acid to enable intestinal enzyme-mediated hydrolysis and preferential lower-gastrointestinal delivery of mesalamine. Preclinical studies reported prolonged mesalamine exposure in ileal and colonic tissue, lower systemic exposure, and improved activity relative to sulfasalazine in an acute dextran sodium sulfate mouse colitis model. Cellix Bio completed an FDA Pre-IND meeting for the program in 2018.
Beyond the preview
Go deeper on CLX-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLX-103.